Under the submission, the device company can seek FDA feedback on its planned submission of an Investigational Device Exemption. Feedback could include comment on proposed study design or statistical analysis plan.
The ReActiv8 is designed for the treatment of chronic lower back pain.
More Articles on Devices:
4 New Mazor Robotic Spine Surgery Systems Sold in Q2
10 Observations on the Global Sports Medicine Device Market
Amedica Secures $26M Funding: 5 Things to Know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
